Vascular Intervention // Coronary

Orsiro

Hybrid Drug-Eluting Stent Indicated for discrete de novo stenotic lesions and in-stent restenotic lesions



- Performs as best in class
- Bioabsorbable polymer for controlled drug release of a limus drug
- Proven PRO-Kinetic Energy / PK Papyrus stent design provides exceptional deliverability to access a wider range¹ of lesions

¹ Indication as per IFU



Orsiro Hybrid DES

The Orsiro Hybrid Drug-Eluting Stent brings the optimal combination of effortless deliverability, coupled with a hybrid coating for treating coronary artery stenosis. This unique concept opens a new generation of drug-eluting stents for improving patient outcomes even with long lesions.

Performs as best in class



Advanced technology, better results

Hybrid coating – **BIOlute** and **proBIO** – for optimal performance

- BIOlute active coating consists of the most proven limus family drug and a bioabsorbable polymer matrix (PLLA) which achieves a controlled drug release.
- proBIO passive coating is a silicon carbide, semi conductive sealant, that reduces the interaction between tissue or blood with the metallic surface of the stent.

1. Controlled drug release

2. Bioabsorption





Immediately following implantation the drug elution from **BIOlute** starts. In vivo studies show complete drug release in approximately 100 days.

Optimal and complete drug release⁴

Low inflammatory response due to Poly-L-Lactide (PLLA) polymer matrix⁵

inflammation.



[%]

esults, inflammation score. Overstretched minipig coronary artery model. Number of vessels 88. BIOTRONIK data on file

The gentle break down of the **BIOlute** polymer matrix into CO, and H₂O causes minimal tissue burden and avoids

3. Inert backbone



When the **BIOlute** coating is gone only a proBIO sealed stent is left in the arterial wall.

Up to 96 % reduction of allergenic metal ions with proBIO coating⁶

Orsiro Hybrid Drug-Eluting Stent

Technical Data

Stent						
Stent material	Cobalt chromium, L-605					
Passive coating	proBIO (Amorphous Silicon Carbide)					
Active coating	BIOLute bioabsorbable Poly-L-Lactide (PLLA) eluting a limus drug					
Drug dose	1.4 μg/mm²					
Strut thickness	t thickness Ø 2.25 - 3.0 mm: 60 μm (0.0024"); Ø 3.50 - 4.0 mm: 80 μm (0.0031")					
Delivery system						
Catheter type	Rapid exchange					
Recommended guide catheter	5F (min. I.D. 0.056")					
Lesion entry profile	0.017"					
Guide wire diameter	0.014"					
Usable catheter length	140 cm					
Balloon material	Semi Crystalline Polymer material					
Coating (distal shaft)	Hydrophilic coating					
Marker bands	Two swaged platinum-iridium markers					
Proximal shaft diameter	2.0F					
Distal shaft diameter	2.6F: ø 2.25 - 3.5 mm; 2.8F: ø 4.0 mm					
Nominal pressure (NP)	8 atm					
Rate burst pressure (RBP)	16 atm					

Compliance Chart		Balloon diameter x length (mm)							
		ø 2.25 x 9-40	ø 2.50 × 9-40	ø 2.75 × 9-40	ø 3.00 × 9-40	ø 3.50 × 9-40	ø 4.00 × 9-40		
Nominal Pressure	atm*	8	8	8	8	8	8		
(NP)	ø (mm)	2.25	2.50	2.75	3.00	3.50	4.00		
Rated Burst Pressure	atm*	16	16	16	16	16	16		
(RBP)	ø (mm)	2.50	2.77	3.05	3.33	3.88	4.44		

* 1 atm = 1.013 bar

Ordering Information	Stent ø (mm)	Catheter length 140 cm Stent length (mm)								
		9	13	15	18	22	26	30	35	40
	2.25	364469	364475	364481	364487	364499	364505	364511	391234	391238
	2.50	364470	364476	364482	364488	364500	364506	364512	391235	391239
	2.75	364471	364477	364483	364489	364501	364507	364513	391236	391240
	3.00	364472	364478	364484	364490	364502	364508	364514	391237	391241
	3.50	364473	364479	364485	364491	364503	364509	364515	391018	391020
	4.00	364474	364480	364486	364492	364504	364510	364516	391019	391021

Orsiro is part of the BIOTRONIK coronary solutions portfolio, including:

- Stents: PRO-Kinetic Energy, PK Papyrus Balloons: Pantera Lux, Pantera LEO, Pantera, Pantera Pro
- Guide Wires: Galeo, Galeo Pro, Cruiser, Magnum

For ordering please contact your local sales representative

BIOTRONIK AG Ackerstrasse 6 8180 Bülach - Switzerland Tel +41 (0) 44 8645111 Fax +41 (0) 44 8645005 info.vi@biotronik.com www.biotronik.com

BIOTRONIK AG – All rights reserved. Specifications are subject to modification, revision and improvement.